RCS - Genflow Biosciences - Genflow Signs Master Services Agreement

Genflow BiosciencesAnnouncement

28/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250528:nRSb2547Ka&default-theme=true

RNS Number : 2547K  Genflow Biosciences PLC  28 May 2025

28 May 2025

 

Genflow Biosciences Plc

Genflow Biosciences and CER Sign Master Service Agreement to Strengthen
Long-Term R&D Collaboration

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"),
the only publicly listed longevity company in Europe, is pleased to announce
the signing of a Master Service Agreement (MSA) with CER Groupe (CER), a
long-standing partner of the Company.

CER is a private Belgian research center offering integrated bioproduction and
pre-clinical services within a regulated ISO and GxP-compliant environment.
The MSA formalizes the working relationship between Genflow and CER, providing
a robust R&D framework to accelerate Genflow's pre-IND gene therapy
programs.

Under the terms of the MSA, Genflow and CER will:

·      Develop, produce and characterize Genflow's gene therapy
candidates;

·      Implement a collaborative project management system to drive
efficient execution and timely deliverables supporting Genflow's goals with
standardized templates for Task Orders and technical services; and

·      Combine scientific expertise derisks, innovate and ensure
relevant scientific outcomes.

Said Dr. Eric Leire, CEO of Genflow: "Our partnership with CER has been
instrumental in supporting our R&D efforts to date. Formalizing this
collaboration through the MSA will enable greater operational alignment and
strategic agility as we continue to accelerate our pipeline."

Contacts

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32-477-495-881      +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com

 

 Corporate Brokers
 Capital Plus Partners Ltd
 Jon Critchley, +44 0203 821 6168

 

About Genflow Biosciences

 

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, works through the delivery of a
centenarian variant of the SIRT6 gene which has yielded promising preclinical
results. Genflow's 12-month proof-of-concept clinical trial evaluating their
SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other
programs planned for 2025, include a clinical trial that will explore the
potential benefits of GF-1002 in treating MASH (Metabolic
Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver
disease for which there is no effective treatments.

 

Please visit www.genflowbio.com (http://www.genflowbio.com)   and follow the
Company on LinkedIn
(https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true) and
X (https://x.com/genflowbio) .

 

About CER Groupe

 

CER Groupe is a GLP-certified private Belgian research center supporting
European life sciences innovation for more than 45years. CER's 200 colleagues
gather cutting-edge expertise ensuring high quality integrated bioproduction
and non-clinical services. CER supports companies in progressing their
development from idea generation up to IND-enabling studies. CER Groupe favors
collaborative and agile approaches accelerating companies' access to clinical
stage development.

 

Visit www.cergroupe.be (http://www.cergroupe.be) to learn what CER's partners
say and follow CER Groupe on LinkedIn to stay up-to-date on CER's latest
developments.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPPUMUAUPAGGM